SCHEMBL23748274

SCHEMBL23748274

C=CCOc1ccccc1C(O)c1cccc(F)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
SLC6A9 P48067 1/20 0.41
SLC6A5 Q9Y345 1/20 0.41
HTR2A P28223 4/20 0.40
SLC6A4 P31645 2/20 0.40
SLC22A1 O15245 1/20 0.40
LMNA P02545 1/20 0.40
CYP1A2 P05177 1/20 0.40
ADRB2 P07550 1/20 0.40
ADRB1 P08588 1/20 0.40
HTR1A P08908 1/20 0.40
CYP2D6 P10635 1/20 0.40
ADRA1A P35348 1/20 0.40
DRD2 P14416 1/20 0.40
DRD1 P21728 1/20 0.40
HPGD P15428 1/20 0.40
TSHR P16473 1/20 0.40
MAPK1 P28482 1/20 0.40
HSD17B10 Q99714 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24353756 0.92 MAPT (0.46) MAPTL3MBTL1SLC6A9SLC6A5HTR2A
SCHEMBL24354150 0.86 HPGD (0.43) MAPTL3MBTL1HTR2ASLC6A4SLC22A1
SCHEMBL23748186 0.85 MAPT (0.44) MAPTL3MBTL1SLC6A9SLC6A5HTR2A
SCHEMBL24354289 0.85 ADRB2 (0.40) MAPTL3MBTL1HTR2ASLC6A4SLC22A1
SCHEMBL23748266 0.85 MAPT (0.44) MAPTL3MBTL1HTR2ASLC6A4SLC22A1
SCHEMBL23748235 0.84 DRD2 (0.52) MAPTHTR2ASLC6A4SLC22A1LMNA
SCHEMBL23748277 0.84 MAPT (0.49) MAPTL3MBTL1SLC6A9SLC6A5HTR2A
SCHEMBL23748149 0.83 BRD4 (0.38) MAPTL3MBTL1SLC6A9SLC6A5BRD4
SCHEMBL2575339 0.80 SLC6A9 (0.60) MAPTL3MBTL1SLC6A9SLC6A5LMNA
SCHEMBL23748217 0.79 HPGD (0.44) MAPTL3MBTL1HTR2ASLC6A4SLC22A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230002409-A1 MACROCYCLIC FLU ENDONUCLEASE INHIBITORS JANSSEN BIOPHARMA INC (US) 2023-01-05 US disclosed
US-20230002409-A1 MACROCYCLIC FLU ENDONUCLEASE INHIBITORS JANSSEN BIOPHARMA INC (US) 2023-01-05 US disclosed
US-11312727-B1 Macrocyclic flu endonuclease inhibitors Janssen Biopharma, Inc. (US) 2022-04-26 US disclosed
US-11312727-B1 Macrocyclic flu endonuclease inhibitors Janssen Biopharma, Inc. (US) 2022-04-26 US disclosed
EP-3864020-A1 MACROCYCLIC FLU ENDONUCLEASE INHIBITORS Janssen BioPharma, Inc. (US) 2021-08-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230002409-A1 MACROCYCLIC FLU ENDONUCLEASE INHIBITORS ACE, PNP, FEN1 MAPT 2999/4885L3MBTL1 2124/4885SLC6A9 4674/4885
US-11312727-B1 Macrocyclic flu endonuclease inhibitors ACE, FEN1, PNP MAPT 3026/4885L3MBTL1 3042/4885SLC6A9 4764/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.